#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of LY3884961, an innovative gene therapy for patients with Type 1 Gaucher Disease. This open-label, dose-finding study aims to assess the potential of this adeno-associated viral vector therapy in addressing the peripheral manifestations of Gaucher Disease. The trial involves carefully planned dose-finding and expansion periods, offering hope for improved treatment options for individuals living with this rare genetic disorder.

Table of Contents

What is LY3884961?

LY3884961 is an innovative gene therapy being developed for the treatment of Type 1 Gaucher Disease. It is also known by other names such as PR001A and AAV9.CBA.GBA1.A[1]. This therapy is classified as an adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene. In simpler terms, it’s a specially designed virus that carries a corrected version of the gene responsible for Gaucher Disease[1].

How Does LY3884961 Work?

LY3884961 works by using a harmless virus (AAV9) as a delivery vehicle to introduce a healthy copy of the GBA1 gene into the patient’s cells. The GBA1 gene is responsible for producing an enzyme called glucocerebrosidase, which is deficient in people with Gaucher Disease. By providing a functional copy of this gene, the therapy aims to restore the production of the missing enzyme and potentially alleviate the symptoms of the disease[1].

Target Condition: Type 1 Gaucher Disease

LY3884961 is specifically designed to treat Type 1 Gaucher Disease, also known as non-neuronopathic Gaucher Disease. This is the most common form of Gaucher Disease, characterized by:

  • Enlargement of the liver and spleen (hepatosplenomegaly)
  • Low blood platelet counts (thrombocytopenia)
  • Bone problems, including pain and fractures
  • Anemia (low red blood cell count)
Unlike other types of Gaucher Disease, Type 1 typically does not affect the brain or nervous system[1].

Clinical Trial Overview

The clinical trial for LY3884961 is an open-label, dose-finding Phase 1/2 study. It aims to evaluate the safety and tolerability of a single intravenous dose of the therapy in patients with Type 1 Gaucher Disease. The study is divided into two main periods[1]:

  1. Dose Finding Period: This involves up to three cohorts, each with 3 patients. There’s a 4-week gap between patients to allow for safety review.
  2. Expansion Period: One cohort of up to 6 patients will receive the optimal dose determined in the first period.

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key inclusion criteria are[1]:

  • Age 18-65 years
  • Confirmed bi-allelic GBA1 mutations
  • On stable enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years

Some exclusion criteria include:

  • Significant neurological symptoms
  • Severe splenomegaly (enlarged spleen)
  • History of total splenectomy
  • Severe thrombocytopenia (low platelet count)
  • Previous gene or cell therapy

Study Objectives and Endpoints

The main objective of this study is to evaluate the safety and tolerability of LY3884961. Secondary objectives include assessing its clinical and biomarker effects. Some key endpoints being measured are[1]:

  • Incidence and severity of treatment-emergent adverse events
  • Changes in complement proteins and antibodies
  • Changes in spleen volume
  • Changes in platelet count
  • Changes in enzyme activity and protein levels

Potential Benefits and Risks

While LY3884961 shows promise as a potential one-time treatment for Type 1 Gaucher Disease, it’s important to understand that it’s still in the experimental stage. Potential benefits could include improved enzyme function and reduction in disease symptoms. However, as with any gene therapy, there are risks to consider, such as immune reactions or unexpected effects of the viral vector[1].

It’s crucial for patients to discuss the potential benefits and risks thoroughly with their healthcare providers and the study team before considering participation in this clinical trial.

Aspect Details
Study Drug LY3884961 (Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human GBA Gene)
Condition Type 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)
Study Design Open-label, Dose-Finding, Phase 1/2 Study
Primary Objective Evaluate safety and tolerability of LY3884961
Secondary Objectives Assess clinical and biomarker effects of LY3884961
Key Eligibility Criteria Adults 18-65 years, confirmed bi-allelic GBA1 mutations, stable on ERT/SRT for ≥2 years
Study Structure Dose-finding period (up to 3 cohorts of 3 patients) followed by expansion period (1 cohort of up to 6 patients)
Key Endpoints Safety measures, changes in spleen volume, platelet count, GCase enzyme activity, and GluSph levels

FAQ

  • What is LY3884961 and how does it work? LY3884961 is a gene therapy that uses an adeno-associated viral vector serotype 9 to deliver a codon-optimized human GBA gene. It aims to provide a functional copy of the GBA gene, which is defective in Gaucher Disease, potentially addressing the underlying cause of the condition.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults aged 18-65 with confirmed bi-allelic GBA1 mutations, who have been on a stable dose of enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. They must not have significant neurological symptoms or certain other health conditions.
  • What is the structure of the clinical trial? The trial consists of two main periods: a dose-finding period with up to three cohorts of 3 patients each, and an expansion period with one cohort of up to 6 patients at the optimal dose level. There is a staggered approach to patient enrollment to allow for safety monitoring.
  • What are the main objectives of the study? The primary objective is to evaluate the safety and tolerability of LY3884961. Secondary objectives include assessing its clinical and biomarker effects, such as changes in spleen volume, platelet count, and enzyme activity levels.
  • How long will participants be followed in this study? The study includes a long-term follow-up period. Participants must agree to use contraception for the duration of the study and abstain from blood donations for at least the first year. The exact duration of follow-up is not specified in the provided information.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene

  • Study on the Safety and Effects of LY3884961 for Patients with Parkinson’s Disease and a GBA1 Mutation

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

Glossary

  • Gaucher Disease: A rare genetic disorder characterized by the buildup of certain fatty substances in various organs, particularly the spleen, liver, and bone marrow, due to the lack of an enzyme called glucocerebrosidase.
  • Type 1 Gaucher Disease: The most common form of Gaucher Disease, also known as non-neuronopathic Gaucher Disease, which primarily affects organs outside the central nervous system.
  • Gene Therapy: A technique that uses genes to treat or prevent disease. In this case, it involves introducing a functional copy of the GBA gene to address the underlying cause of Gaucher Disease.
  • Adeno-Associated Viral Vector: A virus-based tool used to deliver genetic material into cells. In this study, it's used to carry the corrected GBA gene into the patient's cells.
  • Enzyme Replacement Therapy (ERT): A treatment approach for Gaucher Disease that involves regular infusions of a manufactured enzyme to replace the deficient glucocerebrosidase enzyme.
  • Substrate Reduction Therapy (SRT): A treatment approach for Gaucher Disease that aims to reduce the amount of glucocerebroside that the body produces, thereby decreasing its accumulation in cells.
  • Splenomegaly: Enlargement of the spleen, which is a common symptom in Gaucher Disease.
  • Thrombocytopenia: A condition characterized by abnormally low levels of platelets in the blood, which can occur in Gaucher Disease.
  • GCase: Short for glucocerebrosidase, the enzyme that is deficient in Gaucher Disease.
  • GBA1: The gene that provides instructions for making the glucocerebrosidase enzyme. Mutations in this gene cause Gaucher Disease.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-ly3884961-for-patients-with-type-1-gaucher-disease/